ATC code: N06BX06
Nootropics. Citicoline, as a precursor of key ultra-structural components of the cell membrane (mainly phospholipids), has a broad spectrum of action: helps to restore damaged cell membranes, inhibits the action of phospholipases, preventing excessive production of free radicals and prevent cell death by acting on the mechanisms of apoptosis.
In the acute phase of stroke reduces the amount of damaged tissue, improves cholinergic transmission.
With traumatic brain injury reduces the duration of post-traumatic coma and severity of neurological symptoms.
Citicoline improves observed during hypoxia symptoms: memory loss, emotional lability, lack of initiative, difficulty in carrying out daily activities and self-care. It is effective in the treatment of cognitive, sensory and motor neurological degenerative disorders and vascular etiology.
Because citicoline is a natural compound that is found in the body, classic pharmacokinetic study can not be performed due to the complexity quantification of endogenous and exogenous citicoline.
Ischemic stroke (acute phase); Ischemic and hemorrhagic stroke (the recovery period); traumatic brain injury (acute and recovery period); cognitive impairment in degenerative and vascular diseases of the brain.
Dosage of Phenylpiracetam
Ingestion - 200-300 mg 3 times per day
Intravenous in stroke and traumatic brain injury in the acute period - 1-2 g / depending on the severity of the disease within 3-7 days, with subsequent transition to the intramuscularly introduction or ingestion.
intramuscularly- 0.5-1 g /
From the central and peripheral nervous system: insomnia, headache, dizziness, agitation, tremors, numbness in limbs paralyzed.
From the digestive system: nausea, loss of appetite, changes in liver enzymes.
Allergic reactions: rash, itching skin, anaphylactic shock.
Other: fever; in some cases - a short-term hypotensive effect, stimulation of the parasympathetic nervous system.
Vagotonia (preponderance of parasympathetic part of the autonomic nervous system); childhood and adolescence to 18 years; Hypersensitivity to citicoline.
Pregnancy and lactation
During pregnancy, the use is possible only when the expected benefit of therapy to the mother outweighs the potential risk to the fetus.
If necessary, use of citicoline during lactation should decide the issue of termination of breastfeeding, as data on the allocation of citicoline in breast milk are not available.
Do not use simultaneously with citicoline drugs containing meclofenoxate.
Citicoline enhances the effects of L-dihydroxyphenylalanine.